Aurinia Pharmaceuticals has delivered a 50.1% gain over the past three years, yet its valuation checks still point to the stock looking cheap on several fronts. Recent share price softness adds to the question of whether the current US$14.57 level is giving investors a discount or simply reflecting caution about the business.
- The 50.1% return over three years suggests patient shareholders have already seen meaningful value created, which raises the bar for new buyers.
- Future growth in Aurinia Pharmaceuticals' revenue and cash flow could support the current price, while any disappointment in execution or profitability may quickly influence what investors are willing to pay.
- Aurinia Pharmaceuticals scores highly on our broader checks, with 5 out of 6 valuation tests indicating that the shares are trading on the cheap side.
The issue now is whether Aurinia Pharmaceuticals' current valuation still leaves enough potential upside to compensate for the risks that come with the stock.
Find out why Aurinia Pharmaceuticals' 24.5% return over the last year is lagging behind its peers.
Is Aurinia Pharmaceuticals a Bargain on Earnings?
The P/E multiple suits Aurinia Pharmaceuticals because the company is already generating earnings that can be compared directly with peers. Aurinia Pharmaceuticals currently trades on a P/E of about 6.3x, which is far below the Biotechs industry average of 17.1x and well under the peer group average of 39.4x. On simple market comparisons, investors are paying a much lower price for each dollar of earnings than is typical for the sector.
A more tailored fair P/E ratio for Aurinia Pharmaceuticals, which factors in its growth, margins, size and risk profile, sits around 12.5x. That is still roughly double the current 6.3x level. The gap between the present P/E and this fair ratio suggests the market is applying a heavy discount to the stock despite the broader checks indicating value support.
On the P/E multiple, Aurinia Pharmaceuticals stock currently screens as undervalued compared with both its fair ratio and sector benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Aurinia Pharmaceuticals Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Aurinia Pharmaceuticals pick up where the valuation puzzle leaves off. They spell out which paths for revenue, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price. These narratives sit on the company’s Community page so you can see in plain terms what future is embedded in the current numbers and judge over time whether that story is still holding up.
One of the top community narratives on Aurinia Pharmaceuticals: 31% undervalued
"Aritinercept is Aurinia Pharmaceuticals’ emerging autoimmune asset, built around a dual BAFF/APRIL inhibition mechanism intended to modulate B cell activity..."
Read one of the top narratives on Aurinia Pharmaceuticals
Do you think there's more to the story for Aurinia Pharmaceuticals? Head over to our Community to see what others are saying!
The Bottom Line
Aurinia Pharmaceuticals still screens as undervalued on earnings, with the current P/E sitting well below both sector averages and a tailored fair ratio. That discount only helps if the company can deliver on the business outcomes that investors are implicitly building into those valuation checks. The key question now is whether earnings quality and growth can support a higher multiple, or whether the low valuation is the market pricing in execution and profitability risk. That tension between a cheap-looking P/E and the uncertainties around future delivery is likely to be the most important factor from here.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com